The oxidative phosphorylation inhibitor atovaquone (ATO) and the photosensitizer new indocyanine green (IR820) were self-assembled into carrier-free nanodrugs (IR820/ATO NPs) to achieve superior photothermal therapy (PTT), offering an attractive mitochondrial metabolism-regulatable approach for breast cancer treatment, where adenosine triphosphate (ATP) was downregulated along with downregulating the expression of heat shock proteins (HSPs) to amplify the sensitivity of PTT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/d1cc02755g | DOI Listing |
Publication Analysis
Top Keywords
amplify sensitivity
8
photothermal therapy
8
mitochondrial-metabolism-regulatable carrier-free
4
carrier-free nanodrug
4
nanodrug amplify
4
sensitivity photothermal
4
therapy oxidative
4
oxidative phosphorylation
4
phosphorylation inhibitor
4
inhibitor atovaquone
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!